Inspire Medical Systems (NYSE:INSP) Issues Quarterly Earnings Results

Inspire Medical Systems (NYSE:INSP) released its earnings results on Monday. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.38, FiscalAI reports. The firm had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. Inspire Medical Systems had a return on equity of 8.86% and a net margin of 15.03%.The company’s quarterly revenue was down 7.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.45 earnings per share. Inspire Medical Systems updated its FY 2026 guidance to 1.050-1.450 EPS.

Here are the key takeaways from Inspire Medical Systems’ conference call:

• Second-quarter revenue fell 7.6% to $200.6 million as coding and reimbursement disruptions, including lower prior authorizations, weighed on procedure volume. Management estimated the quarter’s revenue was reduced by approximately $40 million by these issues.
• Inspire raised its full-year 2026 outlook to revenue of $835 million–$875 million, adjusted operating margin of 4%–6%, and adjusted diluted EPS of $1.05–$1.45, citing better-than-expected second-quarter profitability and improving reimbursement trends.
• Coding clarity is improving as C-codes are now in place, while CMS has proposed 2027 facility reimbursement increases of approximately 12% for hospitals and 15% for ASCs. However, final rates are not expected until November, and physician reimbursement is proposed to decline about 4%.
• Project Horizon is expected to create approximately $30 million of annualized investment capacity for patient access, education, prior-authorization support, and post-implant engagement, with the company expecting the greatest growth benefit in 2027 and beyond.
• Project Horizon will generate $20 million–$25 million of pre-tax restructuring charges, with roughly 90% expected in the third quarter, while third-quarter revenue is forecast to decline 8%–10% year over year and adjusted operating income is expected to be approximately breakeven.

Inspire Medical Systems Stock Down 6.4%

Shares of INSP stock traded down $4.08 during mid-day trading on Wednesday, reaching $60.06. 310,425 shares of the stock traded hands, compared to its average volume of 1,165,575. The company has a market cap of $1.73 billion, a price-to-earnings ratio of 13.38, a price-to-earnings-growth ratio of 5.29 and a beta of 0.70. The stock’s fifty day simple moving average is $46.59 and its two-hundred day simple moving average is $54.97. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Inspire reported adjusted earnings of $0.14 per share, versus the consensus estimate for a $0.24 loss, while revenue of $200.6 million topped expectations of approximately $194.7 million. However, revenue still declined 7.6% year over year. Inspire Medical Systems Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised its fiscal 2026 earnings guidance. Inspire now expects EPS of $1.05 to $1.45, above the roughly $0.91 analyst consensus. Its revenue forecast of $835 million to $875 million is broadly consistent with Wall Street expectations, supporting the stock’s recent rally. Inspire Medical Q2 Earnings Beat Estimates, 2026 View Raised
• Positive Sentiment: Analyst sentiment improved. Oppenheimer upgraded INSP to “outperform” with an $85 price target, while Mizuho raised its target to $65 and retained an “outperform” rating. These revisions suggest analysts see upside after the earnings beat. Inspire Medical Systems Analysts Raise Their Forecasts
• Neutral Sentiment: JPMorgan and Baird also raised their price targets, but kept “neutral” ratings at $60 and $59, respectively, indicating that some analysts view much of the near-term recovery as already reflected in the stock. Analyst Price Target Updates
• Negative Sentiment: Investors continue to face risks from U.S. reimbursement pressures and lower year-over-year revenue. The earnings improvement also compares with $0.45 per share in the prior-year quarter, highlighting ongoing growth and profitability concerns despite the guidance increase. Inspire Medical Systems Announces Second Quarter Results

Wall Street Analyst Weigh In

INSP has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on Inspire Medical Systems from $54.00 to $60.00 and gave the stock a “neutral” rating in a research report on Tuesday. Truist Financial reissued a “hold” rating and set a $62.00 target price (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday. Freedom Capital raised shares of Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. Stifel Nicolaus set a $75.00 price target on shares of Inspire Medical Systems in a research note on Tuesday. Finally, Zacks Research upgraded shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $68.00.

Institutional Trading of Inspire Medical Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC boosted its holdings in Inspire Medical Systems by 40.2% in the fourth quarter. Virtu Financial LLC now owns 5,712 shares of the company’s stock valued at $527,000 after acquiring an additional 1,639 shares during the last quarter. Invesco Ltd. boosted its position in Inspire Medical Systems by 181.7% during the fourth quarter. Invesco Ltd. now owns 261,374 shares of the company’s stock valued at $24,107,000 after acquiring an additional 168,587 shares during the last quarter. Corient Private Wealth LLC acquired a new stake in Inspire Medical Systems during the 4th quarter worth about $337,000. Regal Partners Ltd raised its position in shares of Inspire Medical Systems by 107.7% in the 4th quarter. Regal Partners Ltd now owns 211,304 shares of the company’s stock worth $19,489,000 after acquiring an additional 109,590 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at about $61,619,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.